Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $57.2 million.

  • Crinetics Pharmaceuticals' Net Cash Flow rose 278.47% to $57.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.4 million, marking a year-over-year decrease of 218.28%. This contributed to the annual value of $209.6 million for FY2024, which is 843.34% up from last year.
  • Crinetics Pharmaceuticals' Net Cash Flow amounted to $57.2 million in Q3 2025, which was up 239.99% from -$40.8 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Net Cash Flow's 5-year high stood at $341.0 million during Q1 2024, with a 5-year trough of -$170.0 million in Q1 2025.
  • Its 3-year average for Net Cash Flow is $7.1 million, with a median of -$1.6 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Crinetics Pharmaceuticals' Net Cash Flow was 3,902.19% (2024), while the steepest drop was 5,613.71% (2024).
  • Over the past 5 years, Crinetics Pharmaceuticals' Net Cash Flow (Quarterly) stood at $39.2 million in 2021, then plummeted by 95.50% to $1.8 million in 2022, then slumped by 5,091.37% to -$87.9 million in 2023, then skyrocketed by 40.02% to -$52.7 million in 2024, then spiked by 278.47% to $57.2 million in 2025.
  • Its Net Cash Flow was $57.2 million in Q3 2025, compared to -$40.8 million in Q2 2025 and -$170.0 million in Q1 2025.